European Pharmaceutical Review

JANUARY 30, 2023

In its first meeting of 2023, the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) recommended four new medicines for approval, providing positive opinions for two type 2 diabetes drugs.

Diabetes 96

Diabetes Generic Medicine 96

European Pharmaceutical Review

JULY 25, 2023

billion in 2022. The small molecule API market is influenced by several factors, including heightened R&D within the pharmaceutical sector, a growing prevalence of chronic illnesses and rising demand for generic medicines. This is a rise from $162.8 A compound annual growth rate (CAGR) growth of 5.9

Compounding 97

Compounding Generic Medicine Drug Development Diabetes 97

Pharmaceutical Technology

FEBRUARY 18, 2023

The company offers generic medicines and biosimilars through Sandoz. The company reported revenues of (US Dollars) US$51,742 million for the fiscal year ended December 2022 (FY2022), a decrease of 2.1% Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). over FY2021.

Diabetes 40

Diabetes Generic Medicine Biosimilars Immunity 40

Express Pharma

JULY 3, 2023

India is known as the ‘Pharmacy of the World’, as the generic medicine supplier for over 200 countries, both developed and emerging markets. A large presence of local players producing branded generics, along with lower price levels, has provided India with a unique opportunity. How poised are you to leverage them?

Biosimilars 73

Biosimilars Drug Development Generic Medicine Diabetes 73

Quality Matters

JUNE 12, 2023

Complex generics: The need and challenges Generic medicines have benefited millions of Americans and saved trillions of dollars. Accounting for approximately 90% of prescriptions filled in the United States , generic medicines are essential to increasing patient access to important drug therapies.

Generic Medicine 52

Generic Medicine Dosage Prescription Filling Diabetes 52

Pharmaceutical Technology

MAY 3, 2023

In recent years, first generics have improved patient access to essential treatments and offered affordable treatment options for patients with multiple sclerosis, asthma, heart disease, diabetes, and even the flu. However, that percentage of multiple first generics is not very high—approximately 10.6% from 2001 to 2022.”

Generic Medicine 98

Generic Medicine Drug Development Communication Diabetes 98